Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

Université de Sherbrooke

$25,000.00

14-3-3 eta as a new invadosome regulatory molecule

EF 2016-17

Résumé
Augurex is a Canada based biotechnology company focused on developing novel biomarker blood tests thatassist with early diagnosis, optimization of treatment and disease monitoring. The extracellular 14-3-3etaprotein represents Augurex's first commercialized blood test, JOINTstatTM, for the diagnosis and managementof rheumatoid arthritis, is now distributed in Canada, Europe and Australia. Augurex has found that among theseven 14-3-3 isoforms, the 14-3-3eta protein is present in the joints of patients with this connectivetissue-associated diseases and appears to play a role in the remodeling of the extracellular matrix (ECM)through the regulation of matrix metalloproteinase (MMP) expression. Establishing a link between 14-3-3etaand the basic mechanisms of joint matrix remodeling has proven to be a challenge, due, in part, to the lack of invitro experimental assays for assessing this complex process. The laboratory of Professor Claire Dubois hasbeen the first demonstrate the involvement of actin-rich cell membrane protrusions called invadosomes in jointremodeling. The laboratory has developed a fluorescent invadosome formation assay to visualize thesestructures. This technology can be used to further our understanding of how invadosomes form and function inconnective tissue and determine roles for novel proteins involved in tissue remodeling. The aim of this projectis to link 14-3-3 proteins to extracellular matrix remodeling using invadosome assays. Such information willbroaden our understanding of the role of 14-3-3eta in tissue remodeling. Moreover, using 14-3-3eta as a modelfor examining the mechanism of joint matrix degradation, this study will further validate a new method, theinvadosome assay, for assessing the role of proteins in tissue remodeling. With an increase to research anddevelopment resources, the invadosome assay can be applied to other studies of Augurex's 14-3-3-centricautoimmune portfolio, such as the development of new products aimed at interfering with 14-3-3-relatedfunctions in joint remodeling.
Programme
Engage Grants Program
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
501325-2016
Name nom
Dubois, Claire
Department département
Pédiatrie
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5106
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Extra-cellular matrix
Research subject fr
Matrice extra-cellulaire
Partie
1
Nb partie
1
Application title
14-3-3 eta as a new invadosome regulatory molecule
Keyword
NSERC
Application summary
Augurex is a Canada based biotechnology company focused on developing novel biomarker blood tests thatassist with early diagnosis, optimization of treatment and disease monitoring. The extracellular 14-3-3etaprotein represents Augurex's first commercialized blood test, JOINTstatTM, for the diagnosis and managementof rheumatoid arthritis, is now distributed in Canada, Europe and Australia. Augurex has found that among theseven 14-3-3 isoforms, the 14-3-3eta protein is present in the joints of patients with this connectivetissue-associated diseases and appears to play a role in the remodeling of the extracellular matrix (ECM)through the regulation of matrix metalloproteinase (MMP) expression. Establishing a link between 14-3-3etaand the basic mechanisms of joint matrix remodeling has proven to be a challenge, due, in part, to the lack of invitro experimental assays for assessing this complex process. The laboratory of Professor Claire Dubois hasbeen the first demonstrate the involvement of actin-rich cell membrane protrusions called invadosomes in jointremodeling. The laboratory has developed a fluorescent invadosome formation assay to visualize thesestructures. This technology can be used to further our understanding of how invadosomes form and function inconnective tissue and determine roles for novel proteins involved in tissue remodeling. The aim of this projectis to link 14-3-3 proteins to extracellular matrix remodeling using invadosome assays. Such information willbroaden our understanding of the role of 14-3-3eta in tissue remodeling. Moreover, using 14-3-3eta as a modelfor examining the mechanism of joint matrix degradation, this study will further validate a new method, theinvadosome assay, for assessing the role of proteins in tissue remodeling. With an increase to research anddevelopment resources, the invadosome assay can be applied to other studies of Augurex's 14-3-3-centricautoimmune portfolio, such as the development of new products aimed at interfering with 14-3-3-relatedfunctions in joint remodeling.